CRISPR Therapeutics AG (CRSP)

Market Cap	3.46B
Revenue (ttm)	202.83M
Net Income (ttm)	-239.59M
Shares Out	85.35M
EPS (ttm)	-2.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,347,554
Open	41.00
Previous Close	40.30
Day's Range	40.45 - 41.55
52-Week Range	36.52 - 91.10
Beta	1.67
Analysts	Buy
Price Target	77.13 (+90.3%)
Earnings Date	Feb 19, 2025

About CRSP

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company’s lead product cand...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 19, 2016
• Employees: 407
• Stock Exchange: NASDAQ
• Ticker Symbol: CRSP
• Website: https://www.crisprtx.com

Financial Performance

In 2023, CRISPR Therapeutics AG's revenue was $371.21 million, an increase of 30885.48% compared to the previous year's $1.20 million. Losses were -$153.61 million, -76.37% less than in 2022.

Analyst Forecast

According to 19 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is $77.13, which is an increase of 90.30% from the latest price.

Price Target

$77.13

(90.30% upside)

Analyst Consensus: Buy